A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
Phase 3
Withdrawn
- Conditions
- Plaque-type Psoriasis
- Interventions
- Drug: Placebo to MK-3222Drug: MK-3222 100 mgDrug: MK-3222 200 mg
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Registration Number
- NCT01936688
Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 268
- Registration Number
- NCT01808547
Efficacy and Safety Of Spil's Estradiol Vaginal Tablet
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 49
- Registration Number
- NCT01753102
- Locations
- 🇮🇳
Biniwale Clinic Pvt. Ltd,, Pune, Maharashtra, India
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
Phase 3
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 1090
- Registration Number
- NCT01729754
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
Phase 3
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 772
- Registration Number
- NCT01722331
Pharmacokinetic and Pharmacodynamic Study of Cyclofem
Phase 1
Completed
- Conditions
- Contraception
- Interventions
- Drug: Injection Cyclofem
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 17
- Registration Number
- NCT01699022
- Locations
- 🇺🇸
Clinical Research Center Norfolk, Virginia 601 Colley Avenue,, Norfolk, Virginia, United States
Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 268
- Registration Number
- NCT01576952
Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 558
- Registration Number
- NCT01543490
- Locations
- 🇺🇸
Clinical Research Center, Newport Beach, California, United States
A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Registration Number
- NCT01478555
Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis
Phase 3
Completed
- Conditions
- Blepharitis
- Interventions
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 917
- Registration Number
- NCT01408082
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸Macy Eye Center, Los Angeles, California, United States
🇺🇸Center for Sight, Inc., Fall River, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath